E03-01: New cytotoxics  by Gatzemeier, Ulrich
Copyright © 2007 by the International Association for the Study of Lung Cancer S219
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
patients. We re-conﬁrmed these ﬁndings in an independent cohort of 
56 NSCLC patients. The microRNA signature can distinguish high or 
low-risk patients with signiﬁcantly different survival within stage I, II, 
III, adenocarcinoma or squamous cell carcinoma subgroups of NSCLC 
patients. Our study supports the concept that cancer genomics has great 
potential for clinical application of personalized therapy. 
We also used microarray and lung cancer invasion/metastasis cell line 
model to identify novel biomarkers and treatment targets of lung can-
cer. We have identiﬁed two invasion/metastasis suppressors: CRMP-1 
and HLJ1. The microarray pathway analysis also helps to uncover 
their action mechanisms. The HLJ1-expression inhibited lung cancer 
cell proliferation, tumorigenesis, angiogenesis, cell motility, invasion 
and slowed cell cycle progression through a novel HLJ1/STAT1/ P21 
WAF1 pathway that is P53 and interferon independent. The HLJ1 is co-
regulated by YY1 at enhancer and AP1 at enhancer. HLJ1-expression 
is associated with reduced cancer recurrence and prolonged survival of 
NSCLC patients. These gene signatures and novel biomarkers can be 
used to predict clinical outcome and are potential treatment targets for 
lung cancer patients. 
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Platin doublets are the standard of care in ﬁrst line chemotherapy of 
advanced Non small cell lung cancer. The 1-year survival that can be 
achieved by chemotherapy is around 40 %.
During the past few years the major goal to improve the survival data 
was to include targeted therapies and drugs in the treatment strategy of 
NSCLC.
Stepwise success has been observed with several drugs like EGFR 
inhibitors. Nevertheless, new cytotoxics are under development as well 
to improve even efﬁcacy and optimize toxicity with increased QOL 
during the treatment course.
Novel taxanes:
Docetaxel/Paclitaxel are standards in 1st line combination and as single 
agents in 2nd line treatment for NSCLC. There are limitations for both 
drugs in efﬁcacy, tolerability and feasibility. Drug-conjugates might 
increase accumulation in tumors through enhanced permeation. Ad-
ditionally there is no need for toxic solubilizing agents.
During the last few years we have some new compounds
 Albumin bound Paclitaxel (Abraxane)
 Makromolecule drug conjugate (Xyotax)
 Oral Taxanes (BMS 275183,BAY 598862)
Xyotax was examined within 4 large phase III trials in 1st and 2nd line 
in NSCLC.
 Study design: Stellar 2 (2nd line): Xyotax vs Docetaxel
 Stellar 3 (1st line): Xyotax/Carbo vs Paclitaxel/Carbo
 Stellar 4 (PS2): Xyotax vs Gemcitabine or Vinorelbine
Pioneer : Xyotax vs Paclitaxel
The results so far available showed similar survival,TTP, DCR. In 
women there was a trend towards increased survival. Regarding toxic-
ity there was less myalgia and arthralgia,less alopecia,more nausea 
and vomiting,more grade Ê thrombocytopenia and delayed time to 
neuropathy.
Abraxane was found to have clinical advantages in comparison to Pa-
clitaxel in metastatic breast cancer. The phase I/II program in NSCLC 
is ﬁnished. The drug has activity in NSCLC as sinle agent and in com-
bination. A phase III program is under development.
The oral Taxanes are under investigation still in the phase I/II trials. 
Epothylones:
The rationally designed, fully synthetic epothilone ZK-EPO has 
demonstrated activity against non small cell lung cancer cell lines. The 
results of the ﬁrst completed Phase I study (one 30-min infusion q3w) 
demonstrated good tolerability, with peripheral neuropathy as the most 
common toxicity. Signs of activity, including a promising number of 
objective responses, were reported. A randomised Phase II trial was 
performed to determine the efﬁcacy and safety of ZK-EPO as second 
line therapy (one 3-hour infusion q3w) in patients with stage IIIB and 
IV non small cell lung cancer. 
A total of 44 patients have entered the study. A total of 113 infusions 
were administered to patients. 4 of the ﬁrst 38 evaluable patients did 
show response. The most common drug-related toxicity was peripheral 
sensory neuropathy (< grade 3 in 45% of patients, grade 3 in 14%). 
Seven patients discontinued treatment due to neuropathy. Other drug-
related toxicities (≥ 5%) were myalgia(23%), alopecia (18%), nausea 
(16%), fatigue (16%), vomiting (14%), constipation (9%), arthralgia 
(5%), fever (5%), dizziness (5%), diarrhea (5%), anorexia (5%).
Although the envisaged activity mark was not reached, this preliminary 
data indicate that ZK-EPO, administered as a 3-hour infusion at a dose 
of 16 mg/m2, has promising activity as second line treatment of non 
small cell lung cancer. Peripheral neuropathy currently appears to be 
the only noteworthy toxicity of ZK EPO. 
Pemetrexed:
Pemetrexed is approved in 2nd line treatment in NSCLC. There is 
reasonable activity and good safety proﬁle.
Nevertheless there are a lot of open questions 
activity in 1st line combinations
role of pemetrexed combinations in the adjuvant setting
combined modality treatment + radiotherapy in locally advanced inop-
erable NSCLC 
A lot of randomized trials are underway to answer these questions. 
Some results might be available at the conference.
Customized therapy:
Another aspect to improve chemotherapeutic results during the last 
few years was to develop Ïcustomized therapiesÓ based on pharma-
cogenomic data to select patients with NSCLC having the chance to 
optimize standard chemotherapy.
ERCC1 and RRM1 (DNA repair-enzymes) are such markers which 
have been tested within clinical trials to select patients with platinum- 
or gemcitabine resistance.
High ERCC1 level are correlated with poorer survival after platinum-
based chemotherapy.
Low RRM1 level seemed to be a sign for better gemcitabine-efﬁcacy.
These data must be conﬁrmed within large phase III trials in the future.
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Overall there is a potential for better results even due to conventional 
chemotherapy giving new cytotoxics or selecting patients and treatment 
by pharmacogenomic data.
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Lung cancer results in more than a million deaths annually worldwide 
(1). Non-small cell lung cancer, which comprises of adenocarcinoma, 
squamous cell carcinoma, bronchioloalveolar carcinoma (BAC) and 
large cell carcinoma, accounts for more than 80% of all cases of lung 
cancer. NSCLC is diagnosed at an advanced stage in a majority of the 
patients, for whom systemic therapy remains the mainstay of treatment. 
Systemic therapy also beneﬁts patients with earlier stages of NSCLC, 
since micrometastasis is an early event (2, 3). The availability of newer 
and novel chemotherapeutic agents has contributed to both the survival 
and quality of life beneﬁts for patients with advanced stage NSCLC (4-
6). However, it appears that an efﬁcacy plateau has been reached with 
currently available agents in both the ﬁrst-line and second-line therapy 
of advanced NSCLC (4, 7). 
Molecularly targeted agents provide the ability to modulate events that 
are unique to the cancer cell. Since NSCLC has wide molecular hetero-
geneity, a number of cell signaling pathways are potential targets for 
treatment (8). The targeted agents that have been actively investigated 
for the treatment of NSCLC include EGFR inhibitors, anti-angiogenic 
agents, proteosomal inhibition, inhibitors of the mammalian target of 
rapamycin (mTOR) pathway, matrix metalloproteinase inhibitors and 
protein kinase C inhibitors. Inhibitors of the EGFR and the anti-an-
giogenic pathway are already used for routine care of patients with 
advanced NSCLC and will be discussed elsewhere. 
Proteosome inhibition
The 26 S proteosome is a multi-subunit protein complex that is in-
volved in the degradation of a variety of proteins with critical functions 
such as regulation of the cell cycle, transcription and apoptosis (9). 
Bortezomib is a speciﬁc inhibitor of the 26 S proteosome that has been 
shown in preclinical models to induce apoptosis and enhance the efﬁca-
cy of chemotherapy against a variety of cancer cell lines. It is approved 
for the treatment of multiple myeloma in the US. Based on promising 
preclinical activity, bortezomib has been evaluated for the treatment 
of advanced NSCLC by multiple clinical trials. In a phase II study, ad-
vanced NSCLC patients (N=155) who progressed following one prior 
chemotherapy regimen were randomized to treatment with bortezomib 
alone or in combination with docetaxel (10). The response rate was 8% 
with bortezomib monotherapy compared to 9% with the combination. 
However the median time to progression favored the combination (4 
months vs. 1.5 months). In another phase II study by the SWOG, bort-
ezomib was combined with the regimen of carboplatin and gemcitabine 
for ﬁrst line therapy of advanced NSCLC patients (N=121) (11). The 
combination was tolerated well and was associated with a median 
survival of 11 months. The median time to progression was 5 months. 
Main toxicities associated with the combination included thrombocyto-
penia, neutropenia and neuropathy. Bortezomib has also been evaluated 
in combination with other targeted agents such as EGFR inhibitors by 
preclinical studies. Favorable results have led to early phase clinical tri-
als with novel bortezomib-based combinations. Based on these results, 
bortezomib appears to be an active agent for the treatment of advanced 
NSCLC. Large randomized clinical trials are necessary to determine 
whether the addition of bortezomib to chemotherapy would result in 
improvements in survival for patients with advanced NSCLC.
Histone deacetylase (HDAC) inhibitors
HDAC mediates the transcription of a number of genes relevant for cell 
cycle regulation and apoptosis. By altering the dynamic equilibrium 
between histone acetylation and deacetylation, HDAC inhibitors have 
been noted to exert anti-cancer effects against a variety of cancer cell 
lines (12). The anti-cancer activity of HDAC inhibitors has also been 
attributed to the effects on non-histone targets such as p53, heat shock 
protein 90, alpha tubulin, etc. A number of novel agents that inhibit 
HDAC are currently under development.
Vorinostat (SAHA) is an orally administered inhibitor of HDAC that 
has recently been approved for the treatment of refractory cutaneous 
T-cell lymphoma. Early phase clinical trials with vorinostat have dem-
onstrated activity against mesothelioma and non-small cell lung cancer 
(13). Vorinostat also enhances the activity of other commonly used 
anti-cancer agents such as the platinum compounds and the taxanes 
(14, 15). Therefore, we conducted a phase I study to evaluate the com-
bination of vorinostat with carboplatin and paclitaxel (16). The study 
included 19 patients with previously untreated NSCLC. Vorinostat at 
a dose of 400 mg/day (2 weeks on, 1 week off) was combined safely 
with carboplatin (AUC = 6 mg/ml X min) and paclitaxel (200 mg/m2). 
There were 10 objective responses and 4 had disease stabilization 
out of a total of 19 patients with previously untreated NSCLC. These 
exciting results have led to a phase II study that randomizes patients 
with advanced NSCLC to treatment with carboplatin and paclitaxel in 
combination with either vorinostat or placebo. Vorinostat is also being 
evaluated in combination with a number of targeted agents such as 
EGFR inhibitors. In particular, vorinostat has been shown to have syn-
ergistic interactions with EGFR TKI in resistant cell lines by its effects 
on E-cadherin (17). Therefore, a phase I/II study is being conducted 
to evaluate vorinostat in combination with erlotinib for second line 
treatment of advanced NSCLC. Several other HDAC inhibitors such as 
PXD 101, MS 275 and LBH 589 are also in early phase clinical trials 
for advanced NSCLC. 
mTOR pathway
The mammalian target of rapamycin (mTOR) is a 289 kD serine/threo-
nine kinase, that plays a central role in regulating cell growth, prolifera-
tion and survival (18). mTOR functions downstream of the PI3K/Akt 
pathway which is a major cell survival pathway (19). mTOR is 
dysregulated in several malignancies and has therefore become a target 
for the treatment of cancer. Agents such as CCI-779 (temsirolimus) 
and RAD 001(everolimus) are in various stages of clinical evaluation 
for the treatment of various malignancies. A phase III study conducted 
for patients with advanced renal cell carcinoma demonstrated survival 
advantage for high-risk patients treated with CCI-779 over therapy 
with interferon (20). This has paved the way for extensive evaluation 
of mTOR inhibitors as monotherapy or in combination with established 
agents for the treatment of various malignancies.
In lung cancer, the mTOR inhibitors are under evaluation as mono-
therapy and in combination with proven agents. A phase I/II study 
is evaluating the combination of erlotinib and RAD 001 for patients 
with refractory NSCLC (21). Preliminary results indicated promising 
anti-cancer activity, though the optimal doses are yet to be established 
for the combination. Another ongoing study is evaluating the combi-
nation of geﬁtinib and RAD 001 for advanced NSCLC in the second 
